We report six human Dermatophilus infections diagnosed in Basel between May 2025 and March 2026. The travel-associated first case developed a pustular rash and conjunctivitis after a stay in Thailand. A second imported case occurred after travel to Indonesia. Four subsequent locally acquired cases presented with genital or inguinal folliculitis-like lesions without reported animal contact. Whole-genome sequencing placed all isolates in a monophyletic cluster within the D. congolensis_A lineage, supporting possible human-to-human transmission. Enhanced surveillance and molecular diagnostics are warranted.

Acne vulgaris pathogenesis involves complex interactions between sebum hypersecretion, follicular hyperkeratinisation, microbial colonisation and inflammatory cascades. While the bacterial microbiome has been extensively studied, the role of the skin mycobiome, particularly lipophilic Malassezia species, remains less clearly defined in acne-prone sites. To evaluate evidence for skin mycobiome involvement in acne pathogenesis, a structured narrative review was conducted in PubMed/MEDLINE and PMC, synthesising findings from 14 cross-sectional studies involving 1650 participants from diverse geographic and ancestry backgrounds. Across sequencing and culture-based studies, Malassezia was the dominant fungal genus on healthy as well as acne-prone skin; species-level data most often identified M. restricta and M. globosa, with occasional reports of M. furfur. Although significant variations were observed in fungal abundance, discrepancies exist between studies due to differences in study design, sampling methods (surface swabs vs. comedone or pustule contents vs. pore strips), culture media (lipid-supplemented vs. standard), molecular target (ITS1 rDNA vs. other loci) and population demographics. Multiple sequencing studies did not detect significant fungal alpha/beta-diversity differences between acne and non-acne skin while confirming Malassezia species dominance. One study highlighted the potential underdiagnosis of Malassezia folliculitis in acne patients, suggesting that misdiagnosis may occur due to overlapping clinical presentations. Future studies should predefine primary outcomes, adjust for multiplicity, report sampling depth (surface vs. follicular), specify fungal rDNA region sequenced, use specific lipid-supplemented media for Malassezia isolation when culturing, co-profile bacteria and fungi, and add systematic clinical assessment of Malassezia folliculitis.

Laryngopharyngeal involvement in Behçet's syndrome is rare but clinically significant because it may cause severe odynophagia, dysphagia, and airway compromise. Optimal treatment has not been established, and irreversible structural sequelae, including laryngopharyngeal stenosis and ulcer scarring, may occur. We describe two men with Behçet's syndrome and symptomatic laryngopharyngeal involvement who showed rapid improvement after infliximab administration following an insufficient response to corticosteroids. In case 1, a 25-year-old man was classified as having suspected Behçet's syndrome based on recurrent oral ulcers, pharyngeal ulceration, arthritis, folliculitis-like skin lesions, and previous episodes of abdominal pain. He developed severe pharyngeal pain and dysphagia due to ulcerative lesions extending from the posterior pharyngeal wall to the esophageal inlet. Intravenous prednisolone resulted in limited endoscopic and symptomatic improvement, whereas infliximab promptly relieved pain and restored oral intake, with no recurrence over 14 years of follow-up. In case 2, a 29-year-old man presented with recurrent fever, oral aphthae, genital ulcers, arthritis, erythema nodosum-like lesions, and pharyngeal and laryngeal mucosal lesions associated with dysphagia. His symptoms and laryngoscopic abnormalities improved promptly after infliximab administration following an inadequate response to prednisolone. These cases underscore the importance of considering early anti-tumor necrosis factor-α therapy in steroid-refractory or relapsing laryngopharyngeal Behçet's syndrome, because progression to irreversible structural complications, including stenosis and adhesion, may necessitate surgical intervention if inflammation is not controlled before permanent damage occurs.

Deucravacitinib, an oral selective tyrosine kinase 2 (TYK2) inhibitor, is an effective treatment for chronic plaque psoriasis. Its use is widening to treat other autoinflammatory conditions, but acneiform eruptions have been increasingly reported. The objective was to quantify the incidence of acneiform eruptions with deucravacitinib and compare odds versus placebo, with exploratory analyses by dose and indication. A search of Medline, Embase, and CENTRAL was made for interventional and observational studies. Primary outcome was incidence of acneiform eruption (acne, folliculitis, dermatitis acneiforme, rosacea). Random-effects meta-analysis pooled proportions and odds ratios (OR) was performed. Of 672 records, 14 studies met inclusion. Overall, 467/5,280 (8.8%) developed an acneiform eruption (acne 71.3%, folliculitis 23.3%, dermatitis acneiforme 3.2%, rosacea 2.1%). Across eight controlled studies, pooled incidence was 6.4% (95% CI: 0.05 - 0.09; I2 = 74.9%). Events occurred in 145/2,539 (5.71%) on deucravacitinib versus 9/1,070 (0.84%) controls; pooled OR 4.56 (95% CI 2.28-9.12; I2=9.4%). Discontinuations for acneiform events were uncommon (7/3,317; 0.21%). Dose- and indication-specific analyses suggested higher odds at greater total daily doses and in psoriasis/inflammatory bowel disease. In conclusion, acneiform eruptions are a frequent cutaneous adverse event with deucravacitinib and occur significantly more often than with placebo yet rarely lead to discontinuation.

This systematic review and meta-analysis synthesized evidence on the prevalence and types of diabetes technology-related skin complications in children and adolescents with type 1 diabetes. Thirteen primary studies were included in the systematic review. Five studies involving 796 children and adolescents contributed data to the primary meta-analysis of any skin complication. Using a random-effects model, the pooled prevalence was 63.8% (95% CI 47.8%-77.2%), with substantial heterogeneity (I2 = 92.1%). Among specific complications, the pooled prevalence was 36.7% for scarring/insertion marks, 24.1% for lipohypertrophy, 16.6% for eczema/dermatitis-like reactions, 8.6% for infection/folliculitis, and 5.1% for lipoatrophy. The findings indicate that skin complications are common among young users of insulin pumps and related diabetes technologies, but interpretation is limited by inconsistent definitions, outcome ascertainment, and heterogeneous outcome reporting. Future prospective studies using standardized outcome definitions and consistent skin-assessment methods are needed to clarify risk factors and guide regular skin assessment, site-rotation, and skin-care strategies in pediatric type 1 diabetes care.

Folliculitis is a common inflammatory skin condition for which non-antibiotic topical management options remain limited. This pilot study reports clinical performance, safety, and feasibility data from the use of a medical device gel containing hyaluronic acid (HA) and hydrogen peroxide used in dermatologic practice. Adults aged 18-45 years with a diagnosis of folliculitis applied the gel for 8 weeks according to the instructions for use. Clinical outcomes included lesion count, Total Severity Score (TSS), Investigator Global Assessment of Performance (IGAP), patient satisfaction, and Dermatology Life Quality Index (DLQI). Safety was assessed through adverse event (AE) reporting. Thirteen patients (mean age 30.1±7.7 years) were included. Enrollment rate and study conduct supported the feasibility of a future comparative trial. From baseline to week 8, mean lesion count showed a three-fold reduction, accompanied by a 66.6% improvement in TSS. Investigator- and patient-reported assessments indicated consistent clinical improvement with a positive impact on quality of life. Two mild and transient local effects were reported. Overall, these preliminary observations suggest favorable safety and performance of the gel in routine folliculitis management and support further controlled studies.

Long-standing alopecia areata is a therapeutically challenging subgroup lacking robust evidence regarding Janus kinase (JAK) inhibitors. This retrospective, single-centre study evaluated the efficacy and safety of baricitinib, tofacitinib or ritlecitinib in patients with current alopecia areata episodes lasting ≥8 years, treated between February 2021 and December 2025. Among 41 screened patients, 31 met the inclusion criteria (mean age 24.6±10.1 years; mean episode duration 12.7±4.6 years). The mean baseline SALT score was 62.8±30.2, with 64.5% of patients presenting a baseline SALT score ≥50. At week 24 (n=29), 27.6% and 24.1% of patients achieved absolute SALT scores ≤20 and ≤10, respectively. Relative improvements (SALT30, SALT50 and SALT80) were observed in 48.3%, 31.0% and 24.1% of patients. Treatment discontinuation occurred in 58.1% (18/31) of patients, primarily driven by a lack of efficacy (66.7% of these discontinuations). The most frequent adverse events were folliculitis (22.6%) and acne (12.9%). While the overall therapeutic response to JAK inhibitors remains limited in long-standing alopecia areata, a subset achieves clinically meaningful hair regrowth, supporting their use as a viable treatment option.

Folliculitis decalvans, typically observed in adult males, is rare in pediatric populations. This case report explores the diagnosis and management of a 12-year-old boy with this condition, marking a rare pediatric case in Greece. The patient, a 12-year-old boy of Greek descent, initially presented with symptoms of hair loss beginning at three years of age. Over the years, he developed alopecic patches on the scalp characterized by perifollicular erythema, hyperkeratosis, and tufted hair, accompanied by mild itching and discomfort The report discusses the diagnostic challenges (dermoscopy, histological examination), treatment strategies, and the patient's response to a multimodal treatment regimen.

We describe 17 cases of recurrent facial folliculitis caused by Klebsiella aerogenes bacteria in men who have sex with men in France, Belgium, and the United States. Whole-genome sequencing showed all isolates belonged to sequence type 117 or related lineages. Our findings suggest sexual transmission and highlight emerging clinical and public health concerns.